Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

244 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas.
Garrigues HJ, Tilgen W, Hellstróm I, Franke W, Hellström KE. Garrigues HJ, et al. Among authors: tilgen w. Int J Cancer. 1982 May 15;29(5):511-5. doi: 10.1002/ijc.2910290505. Int J Cancer. 1982. PMID: 7095896
Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines.
Matzku S, Bröcker EB, Brüggen J, Dippold WG, Tilgen W. Matzku S, et al. Among authors: tilgen w. Cancer Res. 1986 Aug;46(8):3848-54. Cancer Res. 1986. PMID: 3731060
Localization of melanoma-associated antigen p97 in cultured human melanoma, as visualized by light and electron microscopy.
Tilgen W, Hellström I, Engstner M, Garrigues HJ, Riehl R, Hellström KE. Tilgen W, et al. J Invest Dermatol. 1983 May;80(5):459-63. doi: 10.1111/1523-1747.ep12558390. J Invest Dermatol. 1983. PMID: 6842000
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.
Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H. Rebmann V, et al. Among authors: tilgen w. Int J Cancer. 2002 Aug 10;100(5):580-5. doi: 10.1002/ijc.10524. Int J Cancer. 2002. PMID: 12124808
L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma.
Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P. Fogel M, et al. Among authors: tilgen w. Cancer Lett. 2003 Jan 28;189(2):237-47. doi: 10.1016/s0304-3835(02)00513-x. Cancer Lett. 2003. PMID: 12490317
Mitofilin and titin as target antigens in melanoma-associated retinopathy.
Pföhler C, Preuss KD, Tilgen W, Stark A, Regitz E, Fadle N, Pfreundschuh M. Pföhler C, et al. Among authors: tilgen w. Int J Cancer. 2007 Feb 15;120(4):788-95. doi: 10.1002/ijc.22384. Int J Cancer. 2007. PMID: 17131336
Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma.
Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U. Ugurel S, et al. Among authors: tilgen w. Int J Cancer. 1999 Aug 27;82(5):727-36. doi: 10.1002/(sici)1097-0215(19990827)82:5<727::aid-ijc17>3.0.co;2-e. Int J Cancer. 1999. PMID: 10417772
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Ugurel S, et al. Among authors: tilgen w. Cancer. 2001 Jul 15;92(2):369-76. doi: 10.1002/1097-0142(20010715)92:2<369::aid-cncr1332>3.0.co;2-u. Cancer. 2001. PMID: 11466692
Expression of CD44 variant isoforms in malignant melanoma.
Seiter S, Schadendorf D, Herrmann K, Schneider M, Rösel M, Arch R, Tilgen W, Zöller M. Seiter S, et al. Among authors: tilgen w. Clin Cancer Res. 1996 Mar;2(3):447-56. Clin Cancer Res. 1996. PMID: 9816190
Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines.
Scheibenbogen C, Keilholz U, Meuer S, Dengler T, Tilgen W, Hunstein W. Scheibenbogen C, et al. Among authors: tilgen w. Int J Cancer. 1993 May 28;54(3):494-8. doi: 10.1002/ijc.2910540323. Int J Cancer. 1993. PMID: 7685328
244 results
Jump to page
Feedback